摘要:

Alcoholic extracts of yeast have been used as the active ingredient in medications under names such as “tissue or skin respiratory factor,” Biodyne (Sperti Drug Co, Cincinnati, Ohio—now defunct), and live yeast cell derivative (LYCD). Beneficial clinical results from the use of LYCD have been reported for the treatment of burns, wounds, and hemorrhoids. The medicinal effects of LYCD have recently been localized to a protein fraction containing a mixture of several peptides. The effects of topical application of the peptide mixture on wounds were examined in diabetic mice, an animal model in which the healing process is disrupted and delayed. Full-thickness wounds were created on the backs of diabetic (DB) and nondiabetic (non-DB) mice. Half of the DB and non-DB mice were treated with 0.05 mL of LYCD after wounding and for 4 successive days. All other mice received vehicle. Wound areas were measured at Day 0 and at 2-day intervals. Mice were sacrificed at 3, 7, 10, 21, and 28 days postinjury. Differences in the extent and quality of healing appeared between DB mice receiving LYCD and DB mice receiving vehicle by day 10 (P< .0001). By 24 days postinjury, DB mice receiving LYCD had achieved 100% wound closure, whereas DB mice receiving vehicle had achieved only 31.4% wound closure. Histologic examination of wounds reflected improved wound healing in DB mice receiving LYCD as compared with those receiving vehicle. A topically applied yeast extract peptide mixture significantly attenuates wound closure and the degree of cellular reorganization of full-thickness excisional wounds of DB mice.

ISSN:0273-8481    

出版商:OVID    

年代:1999

数据来源: OVID

ISSN:0273-8481    

出版商:OVID    

年代:1999

数据来源: OVID

ISSN:0273-8481    

出版商:OVID    

年代:1999

数据来源: OVID

ISSN:0273-8481    

出版商:OVID    

年代:1999

数据来源: OVID

摘要:

SUMMARYAlthough the scalp donor site has been considered to be advantageous for facial reconstructive surgery since it was first used in this manner by Crawford,18the deep scalp donor site has developed associated complications, including concrete scalp.13The incidence of this complication, combined with our concerns related to pain, anxiety, and subsequent risk of surgery with resulting alopecia, led us to investigate a new scalp donor site treatment, the Unna cap. Although both treatment groups yielded similar healing times (11 days), 2 of 3 patients treated with Xeroform gauze (Group 1) went on to develop a concrete scalp deformity requiring significant care and a longer hospital stay, whereas no patients in the Unna cap group (Group 2) developed such complications. In addition, patients in Group 2 reported less procedural pain with the Unna cap. The Unna cap showed a trend toward being more cost-effective because of a decrease in the nursing time required (fewer dressing changes). These findings are consistent with our earlier trial experience. For these reasons, the Unna cap has replaced medicated gauze as the standard treatment for scalp donor sites at our institution.We thank die nurses and therapists of the University of Washington Burn Center who supported this research, especially Margaret Sandvig, RN, BSN, former nurse manager of die acute care burn unit, without whom this study would not have been possible.

ISSN:0273-8481    

出版商:OVID    

年代:1999

数据来源: OVID

ISSN:0273-8481    

出版商:OVID    

年代:1999

数据来源: OVID